Muscular dystrophy drug

Abstract

The object of the present invention is to provide a drug having therapeutic effect on muscular dystrophy without lowering renal function. The therapeutic drug for muscular dystrophy of the present invention comprises a caldecrin or a caldecrin gene.

1 . A muscular dystrophy drug, comprising a caldecrin. 
     
     
         2 . A muscular dystrophy drug, comprising a following protein (a) or a following protein (b):
 (a) a protein having amino acid sequence of SEQ ID No. 1 or SEQ ID No. 2;   (b) a protein formed by deletion, substitution and/or addition of one or several amino acids of a protein having the amino acid sequence of SEQ ID No. 1 or SEQ ID No. 2, and having therapeutic effect on muscular dystrophy.   
     
     
         3 . A muscular dystrophy drug, comprising a caldecrin gene. 
     
     
         4 . A muscular dystrophy drug, comprising a caldecrin gene having a base sequence of SEQ ID No. 3 or SEQ ID No. 4. 
     
     
         5 . A vector, comprising the caldecrin gene according to  claim 3 . 
     
     
         6 . A vector, comprising the caldecrin gene according to  claim 4 . 
     
     
         7 . A transformed cell, comprising the vector according to  claim 5 . 
     
     
         8 . A transformed cell, comprising the vector according to  claim 6 .